NCT07349472

Pentoxifylline in Patients With Ulcerative Colitis

Clinical Study Evaluating Safety and Efficacy of Pentoxifylline in Patients With Ulcerative Colitis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Ihab Elsayed Hassan · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.

Conditions

• Inflammatory Bowel Diseases

Interventions

Type	Name	Description
DRUG	Mesalamine	Mesalamine is the standard first line treatment of ulcerative colitis
DRUG	Pentoxifylline	Pentoxifylline (PTX), a methylxanthine derivative and non-selective phosphodiesterase inhibitor, has been extensively studied for its anti-inflammatory and immunomodulatory actions. It inhibits TNF-α production at the transcriptional level and downregulates several inflammatory cytokines, including IL-1β, IL-6, and interferon-γ

Timeline

• Start date: 2026-01-20
• Primary completion: 2027-01-20
• Completion: 2027-02-20
• First posted: 2026-01-16
• Last updated: 2026-04-15

Locations

1 site across 1 country: Egypt